SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
The widespread adoption of Bcr –Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias Jabbour Tags: Review Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hematology | Leukemia | Lymphoma | Myeloma